First trials evaluating CD19 and CD20 CAR T cells in canine lymphoma [48, 66] showed promising results in that there was limited dose related toxicity and absence of CRS (cytokine release syndrome) which is a major concern in human clinical trials [67]. This evidence concerns the gene CD19 and congenital rubella syndrome.